You are here: Industry Insights > inhibitors

News List

Drug cocktail turns off the juice to cancer cells worldpharmanews
December 12, 2018
A widely used diabetes medication combined with an antihypertensive drug specifically inhibits tumor growth - this was discovered by researchers from the University of Basel's Biozentrum two years ago.
Important pipelines in development of the Liver Cancer Drug Weiyi
December 11, 2018
The angiogenesis inhibitors and immune checkpoint inhibitors are the directions of main liver cancer drugs in development, and the drug combinations are also in development.
CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia prnasia
January 02, 2018
CStone Pharmaceuticals (Suzhou) Co., Ltd. today announced that it has submitted an Investigational New Drug (IND) application to the Human Research Ethics Committee at Ashford Cancer Center in Australia
Novartis' Tasigna Wins FDA Nod for First and Only CML Therapy biospace
December 28, 2017
Novartis announced today that the US Food and Drug Administration (FDA) approved the inclusion of Treatment-free Remission (TFR) data in the Tasigna® (nilotinib) US product label.
U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castrat biospace
December 26, 2017
Apalutamide is the First Agent Submitted for Approval to Treat Earlier Stage Castration-Resistant Prostate Cancer at High Risk for Metastasis
FGF inhibitors may provide a new way to treat high blood pressure europeanpharmaceuticalreview
November 22, 2017
Drugs designed to halt cancer growth may offer a new way to control high blood pressure…
Sanofi buys rights to Principia’s BTK inhibitor pharmatimes
November 13, 2017
Sanofi has bought itself rights to Principia BioPharma’s experimental tyrosine kinase (BTK) inhibitor PRN2246, in a deal potentially worth more than $800 million to the latter firm.
Study Confirms Link Between SGLT2 inhibitors and Diabetic Ketoacidosis drugs.com
June 08, 2017
A new class of type 2 diabetes drugs called SGLT2 inhibitors could increase the risk of a rare, life-threatening complication of the disease called ketoacidosis, a new study warns.

Previous page 1 2 3 Next page